XOMA (XOMA)
(Delayed Data from NSDQ)
$24.00 USD
+0.71 (3.05%)
Updated Jun 11, 2024 04:00 PM ET
After-Market: $23.68 -0.32 (-1.33%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Brokerage Reports
XOMA Corporation [XOMA]
Reports for Purchase
Showing records 321 - 330 ( 330 total )
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
2011 Major Value Drivers in Emerging Pharmaceuticals.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q3 Financials: Cash Runway Through Major Clinical Value Drivers.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q2 Financials a Nonevent. We See Cash Runway Through Important Clinical Data in Q1:11. Fair Value Moves to $1.30.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q2 Financials Preview, Model Update, and Business Outlook.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Life Sciences: Biopharmaceuticals / Biotechnology.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q1 Financials Uneventful. Value Driving Clinical Data Releases Expected in Q4:10 and Q1:11.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q1 Financials Preview, Model Update, and Business Outlook
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
2009 Financials were Uneventful. 2010 Milestones Include Important Clinical Data and a Potential Partnership
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L